Abstract

ObjectivesAmerican College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) is a composite endpoint to assess the likelihood of improvement in diffuse systemic sclerosis. ACR-CRISS is a weighted score...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Correction: New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis
-
Annals of the Rheumatic Diseases | VOL. 80
--
12 Aug 2021
SAT0262 MODIFIED ACR COMPOSITE RESPONSE INDEX IN SYSTEMIC SCLEROSIS SCORE SHOWS SENSITIVITY AND EXTERNAL VALIDATION TO MEASURE MAGNITUDE OF RESPONSE AT 12 MONTHS IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Antonio Carriero ... Giuseppina Abignano
-
Antonio Carriero, et. al.Antonio Carriero ... Giuseppina Abignano
01 Jun 2019
Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time
Connor P Vershel ... Tuan M Tran
Annals of the Rheumatic Diseases | VOL. 81
Connor P Vershel, et. al.Connor P Vershel ... Tuan M Tran
22 Dec 2021
Tackling systemic sclerosis from all angles.
The Lancet Rheumatology
The Lancet. Rheumatology | VOL. 2
The Lancet Rheumatology The Lancet Rheumatology
01 Mar 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers